NYSEAMERICAN:PLX - Protalix Biotherapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.4080 -0.01 (-2.39 %)
(As of 12/11/2018 04:00 PM ET)
Previous Close$0.4201
Today's Range$0.4050 - $0.4299
52-Week Range$0.38 - $0.83
Volume531,674 shs
Average Volume686,542 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.

Receive PLX News and Ratings via Email

Sign-up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PLX
Previous SymbolNYSEMKT:PLX
CUSIPN/A
Phone+972-4-9028100

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees190
Outstanding Shares148,380,000
Market Cap$0.00
OptionableOptionable

Protalix Biotherapeutics (NYSEAMERICAN:PLX) Frequently Asked Questions

What is Protalix Biotherapeutics' stock symbol?

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

How were Protalix Biotherapeutics' earnings last quarter?

Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) issued its quarterly earnings results on Wednesday, November, 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.06. The business earned $0.66 million during the quarter, compared to analysts' expectations of $8 million. During the same period in the prior year, the business posted ($0.09) earnings per share. View Protalix Biotherapeutics' Earnings History.

When is Protalix Biotherapeutics' next earnings date?

Protalix Biotherapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Protalix Biotherapeutics.

What price target have analysts set for PLX?

1 brokerages have issued 1 year price targets for Protalix Biotherapeutics' shares. Their predictions range from $4.00 to $4.00. On average, they anticipate Protalix Biotherapeutics' share price to reach $4.00 in the next year. This suggests a possible upside of 880.4% from the stock's current price. View Analyst Price Targets for Protalix Biotherapeutics.

What is the consensus analysts' recommendation for Protalix Biotherapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix Biotherapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Protalix Biotherapeutics.

What are Wall Street analysts saying about Protalix Biotherapeutics stock?

Here are some recent quotes from research analysts about Protalix Biotherapeutics stock:
  • 1. According to Zacks Investment Research, "Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. " (11/14/2018)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our model yields an rNPV of $213M for PRX-102 using a 15% discount rate and 75% probability of approval, accounting for the Chiesi partnership and receipt of royalties on PRX-102 sales globally. We also ascribe an rNPV of $200M to alidornase alfa, a $100M rNPV for $50M rNPV for OPRX-106, translating into a price per share of $4.00. This assumes 148M shares outstanding as of end-2Q 2019." (9/24/2018)

Has Protalix Biotherapeutics been receiving favorable news coverage?

News coverage about PLX stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Protalix Biotherapeutics earned a daily sentiment score of 1.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term.

Are investors shorting Protalix Biotherapeutics?

Protalix Biotherapeutics saw a decline in short interest in November. As of November 30th, there was short interest totalling 3,008,558 shares, a decline of 0.9% from the November 15th total of 3,034,465 shares. Based on an average trading volume of 130,814 shares, the short-interest ratio is presently 23.0 days. Currently, 2.2% of the shares of the company are short sold. View Protalix Biotherapeutics' Current Options Chain.

Who are some of Protalix Biotherapeutics' key competitors?

Who are Protalix Biotherapeutics' key executives?

Protalix Biotherapeutics' management team includes the folowing people:
  • Mr. Moshe Manor, CEO, Pres & Director (Age 62)
  • Dr. Yoseph Shaaltiel, Founder and Exec. VP R&D (Age 64)
  • Mr. Yossi Maimon CPA, MBA, CFO, VP, Treasurer & Sec. (Age 47)
  • Dr. Einat Brill-Almon, Sr. VP of Product Devel. (Age 58)
  • Mr. Yaron Naos, Sr. VP of Operations (Age 55)

Who are Protalix Biotherapeutics' major shareholders?

Protalix Biotherapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.20%), Fosun International Ltd (1.77%) and Opaleye Management Inc. (1.68%). Company insiders that own Protalix Biotherapeutics stock include Madalena Energy Inc, Moshe Manor, Randall Peel Boyd, Steve Dabner and Terence Stanley Meek. View Institutional Ownership Trends for Protalix Biotherapeutics.

Which institutional investors are selling Protalix Biotherapeutics stock?

PLX stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc.. View Insider Buying and Selling for Protalix Biotherapeutics.

Which institutional investors are buying Protalix Biotherapeutics stock?

PLX stock was bought by a variety of institutional investors in the last quarter, including Fosun International Ltd and Renaissance Technologies LLC. Company insiders that have bought Protalix Biotherapeutics stock in the last two years include Moshe Manor, Randall Peel Boyd, Steve Dabner and Terence Stanley Meek. View Insider Buying and Selling for Protalix Biotherapeutics.

How do I buy shares of Protalix Biotherapeutics?

Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Protalix Biotherapeutics' stock price today?

One share of PLX stock can currently be purchased for approximately $0.4080.

What is Protalix Biotherapeutics' official website?

The official website for Protalix Biotherapeutics is http://www.protalix.com.

How can I contact Protalix Biotherapeutics?

Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.


MarketBeat Community Rating for Protalix Biotherapeutics (NYSEAMERICAN PLX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  133 (Vote Underperform)
Total Votes:  262
MarketBeat's community ratings are surveys of what our community members think about Protalix Biotherapeutics and other stocks. Vote "Outperform" if you believe PLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2018 by MarketBeat.com Staff

Featured Article: Cost of Equity

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel